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Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common inherited sensory and motor peripheral
neuropathy. It is caused by PMP22 overexpression which leads to defects of peripheral myelination, loss of long
axons, and progressive impairment then disability. There is no treatment available despite observations that
monotherapeutic interventions slow progression in rodent models. We thus hypothesized that a polytherapeutic
approach using several drugs, previously approved for other diseases, could be beneficial by simultaneously
targeting PMP22 and pathways important for myelination and axonal integrity. A combination of drugs for CMT1A
polytherapy was chosen from a group of authorised drugs for unrelated diseases using a systems biology approach,
followed by pharmacological safety considerations. Testing and proof of synergism of these drugs were performed
in a co-culture model of DRG neurons and Schwann cells derived from a Pmp22 transgenic rat model of CMT1A.
Their ability to lower Pmp22 mRNA in Schwann cells relative to house-keeping genes or to a second myelin
transcript (Mpz) was assessed in a clonal cell line expressing these genes. Finally in vivo efficacy of the combination
was tested in two models: CMT1A transgenic rats, and mice that recover from a nerve crush injury, a model to
assess neuroprotection and regeneration. Combination of (RS)-baclofen, naltrexone hydrochloride and D-sorbitol,
termed PXT3003, improved myelination in the Pmp22 transgenic co-culture cellular model, and moderately
down-regulated Pmp22 mRNA expression in Schwannoma cells. In both in vitro systems, the combination of drugs
was revealed to possess synergistic effects, which provided the rationale for in vivo clinical testing of rodent models.
In Pmp22 transgenic CMT1A rats, PXT3003 down-regulated the Pmp22 to Mpz mRNA ratio, improved myelination of
small fibres, increased nerve conduction and ameliorated the clinical phenotype. PXT3003 also improved axonal
regeneration and remyelination in the murine nerve crush model. Based on these observations in preclinical
models, a clinical trial of PTX3003 in CMT1A, a neglected orphan disease, is warranted. If the efficacy of PTX3003 is
confirmed, rational polytherapy based on novel combinations of existing non-toxic drugs with pleiotropic effects
may represent a promising approach for rapid drug development.
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Charcot-Marie-Tooth disease (ORPHA166), although rare,
is the most common hereditary peripheral neuropathy
with an estimated prevalence of 1 in 2,500 [1]. Seventy
disease genes have now been identified to cause defects
primarily in long axons or myelinating Schwann cells [2].
Approximately half of the patients belong to the CMT1A
subtype which is caused in the majority of cases by the du-
plication of a 1.5 megabase region of human chromosome
17 containing the myelin gene PMP22 encoding the per-
ipheral myelin protein of 22 kDa. Overexpression of this
gene by 50% results in abnormal Schwann cell differenti-
ation and dysmyelination [3], eventually leading to axonal
loss and muscle wasting. This striking dosage sensitivity
points to the important regulatory function of PMP22
protein both for integrity as well as the function of periph-
eral nerves. Tight reciprocal interactions of neurons and
Schwann cells are essential for peripheral nervous
system (PNS). Axons provide signalling clues necessary
for normal differentiation of Schwann cells, while
Schwann cells not only insulate growing axons, but also
deliver trophic factors supporting neuronal functions
[4]. We hypothesized that polytherapeutic intervention
to treat CMT1A should include agents able both to
normalise PMP22 gene expression, and to improve
axonal dysfunction. As a first step we identified possible
targets for intervention, looking at signalling pathways.
Then we selected compounds known as to interfere with
these pathways, to finally test these compounds in a rat
model of the disease.
Methods
Systems biology analysis
Genes associated with development of Charcot-Marie-
Tooth disease were retrieved from OMIM database (Online
Mendelian Inheritance in Man database: http://www.ncbi.
nlm.nih.gov/omim).
The initial identification and analysis of the poten-
tially affected CMT1A-relevant signalling pathways,
integrating these genes, was made with the help of
Ingenuity (https://analysis.ingenuity.com) and GeneGO
(https://portal.genego.com) databases/bioinformatics tools
and proprietary bioinformatics programs, with subse-
quent filtering and manual curation of the data. This
initial analysis was complemented by manual updating
of the most recent literature findings. The choice of
the drugs was made through matching the emerging
relevant targets using with the help of DrugBank,
Reaxys and Integrity databases (http://www.drugbank.
ca, http://www.elsevier.com/online-tools/reaxys, https://
integrity.thomson-pharma.com). Final selection of candi-
date drugs for functional validation studies included also
analysis of their pharmacological efficacy and safety pro-
files (https://www.medicinescomplete.com).Drugs
(RS)-baclofen (B5399), naltrexone hydrochloride (N3136)
and D-sorbitol (S3889) were all obtained from Sigma-
Aldrich. PXT3003 consisted in the combination of these 3
drugs.
Co-cultures of sensory neurons and Schwann cells
15 days gestation pregnant Wild Type (WT) Sprague
Dawley female rats, bred with CMT1A heterozygous rats
[5], were killed by cervical dislocation and embryos (E15)
were removed from the uterus. Rat Dorsal Root Ganglia
(DRG) cultures were obtained as previously described [6-8]
and performed at Neuronexperts laboratories (Marseille,
France). The cultures were maintained in standard
Neurobasal medium for 7 days to allow Schwann cells to
populate sensory neurites. On day 7, the cultures were in-
cubated with standard neuronal medium containing
50 μg/mL ascorbic acid (in order to initiate basal lamina
formation and myelination) and drugs until 19 days. Our
analyses of myelination were performed after 10–11 days
of incubation. Three separate and independent cultures of
DRG (from Transgenic (TG) embryos male rats) were per-
formed with 6 replicates per condition.
Immuno-staining
Cells were fixed by a cold solution of ethanol (95%) and
acetic acid (5%) for 10 min, permeabilised, and blocked
with PBS containing 0.1% saponin (Sigma) and 10% FBS
(Invitrogen) for 15 min. Then, cells were incubated with a
rabbit polyclonal antibody specific to Myelin Basic Protein
(MBP) (Sigma-Aldrich; M3821). MBP staining was revealed
with Alexa Fluor 568 goat anti-rabbit IgG (Molecular
Probes). Nuclei were counter-stained with Hoechst (Sigma-
Aldrich). 20 pictures per well were taken in the same condi-
tions using the InCell Analyzer™ 1000 (GE Healthcare) with
20 × magnification. Analysis of total length of myelinated
axonal segments and total number of nuclei was automatic-
ally performed with the InCell Analyzer Software. Total nu-
clei count showed consistency in all wells and at each time
point of the experiment.
RT4 schwannoma cultures
RT4-D6P2T cell line was provided by ATCC (CRL-2768,
batch 3993689, mycoplasma-free). Cells were thawed
and cultured at Neurofit facilities (Illkirch, France) in
DMEM medium (ATCC) containing 10% Foetal Bovine
Serum (FBS; ATCC) and 1% antibiotic-antimicotic mix-
ture (Gibco), and maintained in a humidified incubator
at 37°C in 5% CO2-95% air atmosphere. Two days later,
cells were trypsinised and transferred to 12-well plates
(Nunc) at 30,000 cells per well. After 48 h, culture
medium was replaced by DMEM containing drugs with-
out FBS. After 8 h of treatment, cells were washed and
harvested in 100 μL Phosphate Buffer Saline (PBS), then
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was discarded and the pellet was stored at −80°C until
use. Three experiments with two independent cultures
of RT4 were performed and each condition was done in
triplicate.
Animals and housing
CMT1A transgenic rats initial colony was established by a
couple of heterozygous transgenic rats belonging to the
original source [5]. We used only male animals to reduce
potential variability in our experiments [5]. Nevertheless,
male rats are clinically indistinguishable from female
CMT1A rats [9]. Animals were housed and maintained at
Key-Obs (Orléans, France). Two to three animals were
housed per type III polycarbonate cages (Techniplast,
Italy) under standard conditions at constant temperature
(22 ± 1.5°C), hygrometry (50 ± 25%), and lighting condi-
tions (50 Lux in housing room and 13 Lux in experimental
room) with a 12/12 h daylight cycle. CD-1 mice were pro-
vided by Janvier Labs (Saint-Berthevin, France). Mice were
housed at the animal facility of Neurofit (Illkirch, France).
They were group-housed (5–10 mice per cage) and main-
tained in a room with controlled temperature (21–22°C)
and a reversed light–dark cycle (12h/12h). Animals had
free access to food and tap water. Animal procedures were
conducted in strict adherence to the EU Directive of
September 22, 2010 (2010/63/UE). Only male animals
were included in the experiments.
Genotyping
Rat (E15) embryos
A piece of each E15 embryo head (3 mm3) was used for
genotyping. DNA was extracted with the SYBR Green
Extract-N-Amp tissue PCR kit (Sigma), then, quantitative
PCR (qPCR) was performed using the 7500 fast RT-PCR
system and analysed following the manufacturer’s instruc-
tions (Applied Biosystems). The gender of each embryo
was determined using the male Sry [NM_012772]
primers [10] (F: 5′-GAGAGAGGCACAAGTTGGC-3′;
R: 5′-GCCTCCTGGAAAAAGGGCC-3′). The genotyp-
ing of each embryo was determined using the Pmp22
[NM_008885] primers [5]. PCR was performed (20 s at
95°C, 45 cycles of 10 s at 95°C, 10 s at 65°C then 30 s
at 72°C) with the 7500 fast RT-PCR system (Applied
Biosystems).
CMT1A rats (aged 3 weeks)
Total DNA was isolated from ear biopsies by the single-
step purification method with DNeasy blood & Tissue kit
(Qiagen Gmbh) according to the manufacturer’s protocol.
PCR was performed (10 min at 95°C, 45 cycles of 10 s at
95°C, 20 s at 64°C then 20 s at 72°C) with a rapid ther-
mal cycler system (LightCycler® 480 II, 96 wells, Roche)
using LightCycler® 480 SYBR Green I Master (Roche).Rat Pmp22 gene DNA [NM_17037.1] was used as a qual-
ity control of DNA extraction (F: 5′-GACAAACCCCA
GATGGCC-3′, R: 5′-CCGCAGCCACCAGCTATTGGT-
3′). Mouse-specific Pmp22 gene [NM_008885.2] PCR
primers (F: 5′-GACAAACCCCAGACAGTTGA-3′; R: 5′-
CAGGAGCCACCAGCTATTACT-3′) was used to iden-
tify transgenic rats. Primers were synthetised by Eurofins
(MWG Operon, Germany).Sciatic nerve crush
Experiments were performed at Neurofit facilities. Sample
sizes used for analyses were determined based on previous
experience on assay variability. 4–5 week-old CD-1 male
mice were anaesthetised using isoflurane (2.5–3% in air).
The right thigh was shaved and the sciatic nerve was ex-
posed at mid-thigh level (5 mm proximal to the bifur-
cation of the sciatic nerve) and crushed for 10 s twice with
a microforceps (Holtex) with a 90° rotation between each
crush. For sham operated animals, sciatic nerves were ex-
posed but not crushed. Finally, the skin incision was se-
cured with wound clips. Forty two days after the crush,
the tibial nerve was taken out from 6 mice per group to
perform morphometric analyses.Drug treatment
CMT1A rats
Stratification of the animals was based on the weight,
the parent origin and the muscular performances ob-
tained in behavioural tests (bar test and inclined plane
test) performed one week before drug treatment. Ran-
domization of animals was done to avoid bias in animal
studies [11,12]. PXT3003 contained 30 μg/kg (RS)-baclofen,
3.5 μg/kg naltrexone hydrochloride and 1.05 mg/kg D-
sorbitol. Drugs were dissolved in distilled water and
were freshly prepared daily before each per os adminis-
tration. PXT3003 was administered once daily by gavage
with inox steel canula (Dominique Dutscher, 075486) in
a volume of 1 mL/kg. At the dates of behavioural test-
ing, gavages were performed after the test. Ages and
treatment durations of rats are stated in the behaviour
section.CD-1 mice
Drugs were dissolved in distilled water and were freshly
prepared daily before each per os administration. First ad-
ministration of treatment (PXT3003: mix of (RS)-baclofen
(60 or 600 μg/kg), naltrexone (7 or 70 μg/kg) and D-
sorbitol (2.1 or 21 mg/kg)) was performed 30 min after
the crush. From day 1 to day 42, administration was
performed once daily. On test days, mice were treated
1.5 h before Compound Muscle Action Potential (CMAP)
recording.
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of CMT1A rats (9 weeks of treatment, 17 weeks of age)
Total RNA was isolated from RT4 cells using the RNeasy
Micro Kit (Qiagen Gmbh) as described by the manufac-
turer’s protocol (Qiagen-RNeasy Micro Handbook), while
total RNA was isolated from sciatic nerves using Qiazol
(Qiagen Gmbh) followed by the single-step purification
method with RNeasy Mini Kit (Qiagen Gmbh) as de-
scribed by the manufacturer’s protocol (Qiagen-RNeasy
Fibrous tissue Handbook). DNA contamination was re-
moved by RNase-free DNase I (Qiagen-RNase-free DNase
set 1,500 Kunits). RNA concentrations were estimated by
NanoDrop ND-1000. RNA quality control was performed
by Agilent RNA 6000 nano chips on Agilent 2100 Bioana-
lyzer. 80 ng of total RNA was reverse transcribed using
SuperScript™ II Reverse Transcriptase with Oligo(dT)12–
18 (Invitrogen), then, qPCR was performed with a rapid
thermal cycler system (LightCycler® 480 II, Roche). Ampli-
fications were performed (10 min at 95°C, 45 cycles of
10 s at 95°C, 40 s at 60°C then 10 s at 72°C) using
LightCycler® 480 SYBR Green I Master (Roche). The se-
quences of the primers (synthesised by Eurofins) used for
the Reverse Transcription quantitative PCR (RTqPCR)
analyses were: Rps9 [NM_031108.2]: F: 5′-ATCCGC
CAACGTCACATC-3′ and R: 5′-CCGCCACCATAAG
GAGAAC-3′, Pmp22 rat and mouse [NM_17037.1] and
[NM_008885.2]: F: 5′-TGTACCACATCCGCCTTGG-3′
and R: 5′-GAGCTGGCAGAAGAACAGGAAC-3′, Mpz
[NM_017027.1]: F: 5′-TGTTGCTGCTGTTGCTCTTC-




Animals were tested in a random and blind manner for
treatment and outcome measurements. Behavioural ex-
periments and readouts (bar, inclined plane, hot plate,
weight bearing and electrophysiological tests) were per-
formed and validated at Key-Obs and Neurofit facilities
by the examiners who were blinded for the treatment.
Sample sizes used for behavioural analyses were also
determined based on previous experience on assay vari-
ability [9,13].
CMT1A rats
Bar and inclined plane tests were performed on CMT1A
rats after 9 weeks of treatment, 13–17 weeks of age.
Bar test: This test evaluated the muscular strength of
the four paws and the equilibrium performances on a
fixed rod. The rat was placed on its four paws on the
middle of the wooden rod (diameter: 2.5 cm; length:
50 cm). The time spent on the bar (fall latency) in each
trial and the number of falls were recorded. Five succes-
sive trials were performed (180 s max) [5].Inclined plane test: The sliding apparatus [14] of 30 ×
50 cm Plexiglas plane that could be inclined from an
angle of 0° (horizontal) up to 60° was used. For each
angle, two trials separated by 1 min were performed.
Each rat was initially placed on the 25° inclined plane in
the up-headed position (head-up orientation). From
30 min up to 1 h later, the same experiment was per-
formed on a 35° inclined plane. Between the tests, rats
were returned to their cages. The Plexiglas plane was
cleaned after each trial. The performances of rats were
evaluated by a 3-level score from 0 (no slide) to 3 (the
rat slides to the bottom of the plane). The analysis was
performed on the mean score at 25° and 35°.
Hot plate: The animal (after 4 months of treatment,
5 months of age) was placed into a glass cylinder on a
hot plate adjusted to 48°C. The latency of the first reac-
tion of the hind paw either left or right was recorded
(paw lifting or licking, leaps or a jump to escape the
heat). The cut-off time was set to 30 s [15].
Adverse events were monitored along animal experi-
ments by assessment of the following parameters: loss of
weight, lack of appetite, diarrhoea, sneezing, sniffling,
laboured breathing, rough hair coat, hair loss, inactivity,
abnormal grooming behaviour, aggressiveness.
CD-1 mice, hind limb weight bearing
Animals’ weight distribution on the four limbs was
assessed on day 13 using the dynamic weight bearing
test (BioSeb, France) [16]. This disability test consists in
a continuous measurement of all pressure points applied
by a freely moving animal, allowing a quantitative evalu-
ation of the weight imbalance caused by pain. Each
mouse was placed in an 11 × 11 × 22 cm cage with a
44 × 44 sensor cells grid on the floor. The pressure ap-
plied on sensor cells by animal’s paws was recorded at a
10 Hz frequency over a 5 min period. Pressure and sur-
face detection thresholds were determined automatically
for each animal by the Dynamic weight bearing 1.3.2 h
software (Bioseb, France). After the manual attribution
of each pressure point to the corresponding paw, the
mean weight applied on each paw was calculated for sur-
face ratio. Unilateral gait dysfunction was finally evalu-
ated through the ipsi/contralateral hind paw weight and
surface ratio.
Electrophysiology
Electrophysiological studies and readouts were done and
validated at Neurofit laboratories. Rats or mice were
anaesthetised by 2.5–3% isoflurane-air mixture. CMAP
was recorded by needle electrodes placed into the intrinsic
foot muscles of the plantar surface (Keypoint electromyog-
raphy, Medtronic, France). Subcutaneous monopolar nee-
dle electrodes (Medtronic, 9013R0312) were used for both
stimulation and recording. 12.8 mA square wave pulses of
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the CMT1A rats (after 8 months of treatment, 9 months
of age), the latencies of CMAPs elicited by stimulation at
both proximal (hip) and distal (hock) sites were measured.
Motor Nerve Conduction Velocity (MNCV) was esti-
mated by the time interval between two stimulation sites
latencies relative to distance between these sites (with leg
fully extended) [5,17]. For the CD-1 crushed mice (42 days
of treatment), the right sciatic nerve (ipsilateral) was stim-
ulated with single pulse applied at the sciatic notch.
CMAP was recorded by needle electrodes placed at the
gastrocnemius muscle. The amplitude of the action poten-
tial was determined 30 days after the crush.
Nerve histology
Mice (42 days of treatment) or CMT1A rats (after 4 months
of treatment, 5 months of age) were anaesthetised with in-
traperitoneal mixture of ketamine and xylazine (80 mg/kg,
and 15 mg/kg, i.p. respectively). 5 mm segment of the right
sciatic nerve of rats (just above the bifurcation of sciatic
nerve into two branches, in contrast to other studies col-
lecting sciatic nerves at their distal (1/3) ends [3]), or tibial
nerve of mice were excised. Tissues were fixed in 4% glu-
taraldehyde in PBS (Sigma-Aldrich) at 4°C overnight. Then,
nerve samples were rinsed with PBS at room temperature
and post-fixed in 1% osmium tetroxide (EMS, France) for
1 h, rinsed in PBS and dehydrated in serial alcohol solu-
tions (VWR Prolabo), and embedded in Epon. Embedded
tissues were kept at 70°C during the 3 days of polymerisa-
tion. The tissue block was cut with a microtome (Microm,
HM360). Transverse sections 5 μm thick were performed.
Then, 1.5 μm cross section was performed and stained
with 1% of toluidine blue (EMS) for 2 min, rinsed in PBS,
dehydrated in serial alcohol solutions (95% and 100%)
followed by xylene solution substitute (EMS) for 10 min at
room temperature, and mounted in Eukitt (EMS).
Morphometric analyses
Composite image of the entire nerve section of each sam-
ple was obtained using an optical microscope (Nikon
optiphot-2) equipped with a digital camera (Nikon DS-
Fi1). Morphometric analyses were performed with digital
images using Image-Pro Plus software (Media Cybernetics
Inc., USA), which computes the axonal and myelin pixel
sizes after individualisation of each myelinated fibre via
the grey level of toluidine blue-stained myelin sheath.
These two parameters were used to calculate the number
of myelinated axons and the g-ratio (ratio of the inner
axonal diameter to the total outer).
Statistical analyses
Statistical tests were two-tailed and conducted at a 5%
significance level. Sample sizes used for behavioural ana-
lyses were defined on the basis of previous experienceon assay variability [9,13]. Data distribution and within-
group variation were preliminary assessed in order to
guide our methodological choices. Statistical analyses
were performed with Prism (http://www.graphpad.com/
scientific-software/prism) and R (http://cran.r-project.
org). We applied an Analysis of Variance (ANOVA) with
Dunnett’s test for comparison of more than one experi-
mental group to a reference and a Welch’s t-test for
comparison of two experimental groups. These tests are
described to be robust enough to overcome changes in
distribution and variation [18,19]. We performed a com-
bined analysis of all cultures and replicates of in vitro
experimental data to assess myelination in DRG co-
cultures after 10–11 days of treatment, and to study
gene expression in RT4 schwannoma cells. In each
in vitro experimental system (DRG and RT4), data were
normalised to the non-treated vehicle control. In DRG
co-cultures, synergy was assessed by drug combination
analysis with isobologram and calculation of Combination
Index (CI) that compares dosages for a given combination
to those expected to obtain the same combination effect
under a simple additive assumption, and offers a quan-
titative definition for additive effect (CI = 1), synergism
(CI < 1), or antagonism (CI > 1) [20-23]. To study the su-
periority of PXT3003 to its single drugs in RT4 cells, an
ANOVA model was fitted and the difference between the
effect of PXT3003 and the effect of the most efficient drug
(i.e. the drug having the largest effect when compared to
control) was tested using a post-hoc test of contrast.
Kaplan-Meier curves were analysed with a Cox model.
Analyses were adjusted to the age of starting treatment
when appropriate (bar test and inclined plane test). Statis-
tical analysis of linear regression of g-ratio with respect to
the axon diameter was performed on slope.
Results
Systems biology analysis and drug choice
As a first step of our discovery we performed a system-
atic analysis of available data to define a group of signal-
ling pathways important for peripheral nerve structure
and function affected in CMT1A disease (Figure 1 and
Additional file 1). Among them, modular pathways known
to affect myelin gene expression such as cAMP-dependent
mechanisms, neurosteroid signalling and the Akt/Erk
pathway were of particular interest [24-28] (Figure 1A and
Additional file 1A). We hypothesised that these modules
are integrated as a unified system that is influenced by G
protein coupled receptors (GPCRs) leading to the differen-
tial regulation of genes for peripheral myelin proteins.
Since PMP22 is not only a structural component of mye-
lin, but may have signalling functions in Schwann cells, its
transcriptional control could be different from “classical”
myelin genes such as MPZ. The topology of these putative
regulatory networks permitted us to suggest that drugs
Figure 1 Pharmacology network-based drug repurposing for CMT1A disease. For detailed explanations and abbreviations, see Additional file 1.
(A) Three principal pathways regulating expression of PMP22 gene through extracellular GPCR signalling in Schwann cells. The functional interaction
between cAMP pathway, neurosteroid-mediated signalling and PI3K-AKT/ERK kinase cascades, activated by receptor tyrosine kinases, control the expression
of PMP22 gene in Schwann cells. Individual drugs are shown in green. Blue shading: cAMP pathway; green shading: neurosteroid-mediated signalling;
yellow shading: RTK/PI3K-AKT/ERK kinase cascades. (B) Cytoprotective and neuromodulator actions of PXT3003 drug combination in peripheral neurons.
Dysfunction of CMT1A Schwann cells could affect membrane excitability of neuronal cells, leading to abnormal processing of neuronal information,
cytotoxicity and axonal loss. GPCRs, modulated by PXT3003 drugs, are well-known regulators of neuronal excitability and pain sensation, are able to activate
cytoprotective signalling pathways in different experimental settings, and could preserve functional integrity of peripheral neurons in CMT1 patients.
Baclofen, naltrexone and sorbitol are shown in green. Red symbols: established or putative functional targets for PTX3003 drugs. Blue arrows: activation
links; red lines: inhibition links; dashed lines: functional effect link is receptor-type specific.
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robust influence when combined. Thus, we have focused
on the drugs able to modify relevant branches of GPCR
signalling. This class of compounds is functionally pleio-
tropic, acting on multiple pathways and is well represented
in approved pharmacopeia. This fact permitted us to apply
additional safety criteria for their selection. We also pre-
ferred drugs that could be important for other aspects of
peripheral nerve physiology (Figure 1B and Additional file
1B) that are affected in CMT1A, particularly drugs poten-
tially promoting neuronal protection. Eventually, three
drugs – (RS)-baclofen, naltrexone and D-sorbitol – were
chosen for testing in the relevant cellular and animal
models of CMT1A.
The first drug, baclofen (BCL), is a specific agonist of
GABAB receptors. These receptors decrease the activity of
adenylate cyclases and therefore reduce the levels of intra-
cellular cAMP that positively regulate PMP22 expression
[24,25,29-31]. GABAB receptors are also abundant in neu-
rons [32]. BCL is a safe drug currently used to treat spasti-
city. The second selected drug is the opioid receptor
antagonist naltrexone (NTX). It is approved for treating
drug addiction, and was shown at low non-toxic doses, to
potentiate, rather than to block, cell signalling through
opioid receptors that are coupled to inhibitory G alpha
protein subunit (Gαi), thereby reducing intracellular levels
of cAMP. NTX could mediate this action either through
interaction with accessory protein Filamin A (FLNA) [33]
or by induction of endogenous opioid agonists [34]. The
third compound D-sorbitol (SRB), a natural metabolite
playing an important role in the energy production/
storage (polyol pathway), was chosen as another safe drug
involved in processes that are deregulated in CMT1A. No
specific receptor for SRB is currently known although
muscarinic acetylcholine GPCRs, present both on neurons
and Schwann cells and affecting cAMP levels, were re-
ported to bind SRB with unexpected high affinity [35].
Moreover, SRB acting as chaperone might also improve
PMP22 protein folding [36,37] that is impaired when
overexpressed in CMT1A Schwann cells [38,39]. Import-
antly, we hypothesised that a combination of these drugs
(PXT3003), by acting on different receptor systems, could
decrease the toxic effects of the overexpression of PMP22
gene and also improve downstream consequences on
myelination and nerve function. This hypothesis was then
tested in a battery of ex vivo and in vivo tests modelling
different aspects of CMT1A disease.
PXT3003 improves myelination ex vivo
Increased PMP22 copy number in CMT1A patients
causes peripheral nerve dysmyelination through dysba-
lance in the expression of genes for myelin proteins and
consecutive downstream signalling events [3]. It can be
studied in neuron-Schwann cell co-cultures derived fromdorsal root ganglia (DRG) of CMT1A transgenic (TG)
rats, a model of human CMT1A [8,40]. In this model,
axons show reduced amounts of myelinated segments
when compared to the wild-type [40]. We treated DRG
co-cultures from CMT1A rats during 10–11 days with sin-
gle drugs and their combination PXT3003. Myelination
was measured by quantifying myelin basic protein (MBP)-
stained segments of neuronal fibres (Figure 2A and B). We
observed that, acting alone, each of the three drugs im-
proved myelination in a dose-dependent fashion (Figure 2C
to E). Then, we tested their combination PXT3003 and
also demonstrated a dose-related effect on axonal myelin-
ation (Figure 2F) with a synergistic interaction between
the 3 drugs (dose 2) as calculated through Combination
Index analysis (CI = 0.36) and 3D isobologram obtained
from dose-effect curves [23] (Figure 2G), supporting the
concept of an increased drug potency when used in
combination.
PXT3003 modulates Pmp22 mRNA levels in vitro
We then tested the potency of the three drugs to down-
regulate Pmp22 expression in rat RT4 schwannoma when
normalised to the levels of both Actb and Rps9 housekeep-
ing genes [41]. Using a drug ratio corresponding to the
synergistic effect when combined in DRG co-cultures
(Figure 2G, Dose 2), we observed moderately reduced
levels of Pmp22 transcript for single drug treatment with
NTX or SRB (Figure 3A). Importantly, in the PXT3003
drug combination, this effect was increased, i.e. with
significant difference to the single drug action (Figure 3A).
We also found that Mpz mRNA, coding for the major
protein of peripheral myelin, was not affected by our
drugs (Figure 3B), singly or in combination, while the
ratio of Pmp22 to Mpz mRNA was significantly lowered
(Figure 3C) by the drug combination but not by the single
drugs. These results confirmed the importance of com-
bining the chosen drugs and prompted us to use the
PXT3003 combination in further testing in animal models.
PXT3003 down-regulates Pmp22 expression and is active
in the in vivo transgenic rat model of CMT1A disease
PXT3003 was assessed in CMT1A rats [5,9]. These rats
carry additional copies of the murine Pmp22 gene leading
to 1.6-fold overexpression of Pmp22 mRNA in peripheral
nerves. This model is characterised by dysmyelination, re-
duced MNCV, diminished muscle strength and sensory
nerve involvement, mimicking the clinical phenotype of
human CMT1A patients. CMT1A rats have been used
previously to assess the efficacy of progesterone antago-
nists and recombinant Neuregulin 1 (NRG1) as single
drugs [3,9,13,42]. Young adult male Pmp22 TG rats and
their WT littermates were treated during 9 weeks by
daily oral treatment starting at 4 weeks of age. We con-
firmed by RTqPCR analysis the ~1.6-fold up-regulation
Figure 2 BCL, NTX, SRB and their mix (PXT3003) improve myelination in DRG co-cultures. (A) and (B) PXT3003 treatment (Dose 2) of
myelinating DRG co-cultures of neurons and Schwann cells derived from CMT1A transgenic rats (TG) demonstrated an increased length of
MBP-positive fibres (red staining in (B)) compared to the untreated control (A). Scale bar: 56 μm. Blue staining: DAPI. (C) to (F) After 10–11 days
of treatment of TG DRG co-cultures with single compounds BCL (C), NTX (D), SRB (E) or their PXT3003 (F) combination at four doses (Dose 1:
0.32 nM of BCL, 0.32 nM of NTX and 32 nM of SRB; Dose 2: 1.6 nM of BCL, 1.6 nM of NTX and 160 nM of SRB; Dose 3: 8 nM of BCL, 8 nM of NTX
and 800 nM of SRB; Dose 4: 40 nM of BCL, 40 nM of NTX and 4 μM of SRB), myelination was significantly improved (featured by an increased
length of MBP-stained segments). (G) The synergistic potential of PXT3003 (Dose 2: 1.6 nM of BCL, 1.6 nM of NTX and 160 nM of SRB) was
displayed by an isobologram plotted from dose-effect curves of each drug. The calculated Combination Index (CI) of synergy was 0.36; Synergism
is characterized by a CI < 1. Greyed surface represents the concentrations of the mixes at which CI = 1. Three independent DRG co-cultures with
6 replicates each were performed and analysed. +, *P < 0.05; ++, **P < 0.01; ***P < 0.001 vs Vehicle; ANOVA with Dunnett’s test (*) and t-test (+).
Data are shown as mean + SEM. Vhc: Vehicle.
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Figure 3 BCL, NTX, SRB and their mix (PXT3003) down-regulate Pmp22 mRNA expression in RT4 Schwannoma cells. (A) After a
treatment of 8 hours of RT4 Schwannoma cells with single compounds (100 nM of BCL, 100 nM of NTX or 10 μM of SRB) and with PXT3003
combination (100 nM of BCL, 100 nM of NTX and 10 μM of SRB; same drug ratio that was used for all doses in DRG co-cultures), a significant
decrease of Pmp22 mRNA expression level was observed when compared to vehicle (Actb and Rps9 used together as reference genes) with a
significant observed higher efficacy of PXT3003 over single compounds. (B) The same drugs had no effect on Mpz expression (Actb and Rps9
used as reference genes). (C) The expression of Pmp22 with respect to Mpz was significantly decreased after PXT3003 treatment, unlike single
compounds. Three different experiments using 2 cultures each with 3 replicates were performed and analysed. *P < 0.05, ***P < 0.001 vs Vehicle;
ANOVA with Dunnett’s test. #P < 0.05 vs the most active compound; post-hoc contrast test. Data are shown as mean + SEM.
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the TG group when compared to WT littermates
(Figure 4A). In order to examine the ability of PXT3003
to lower Pmp22 gene levels in vivo, we determined the
expression of this gene in sciatic nerves at the end of 9
weeks of PXT3003 treatment. Importantly, we observed its
significant but limited (−12%) down-regulation (Figure 4A)
in line with the in vitro data obtained with Schwannoma
cells (Figure 3C).
Efficacy of 9 weeks of oral daily PXT3003 treatment
given to CMT1A TG rats was assessed by (i) measuring
muscle strength in the bar test, (ii) performance on an
inclined plane and (iii) thermal sensitivity in the hot
plate test. We observed a substantial heterogeneity of
TG rats with respect to muscular strength, as previously
described [13,42]. After 9 weeks of treatment, the overall
mean latency to fall (bar test) was significantly pro-
longed (Figure 4B). The same data set represented as
Kaplan-Meier curves allowed us to confirm the significant
improvement of PXT3003-treated animals (Figure 4C). It
is important to note that the CMT1A-like phenotype
was already manifested before the start of the treatment
(Additional file 2A). We also assessed motor performance
with the inclined plane test [14] that measures the ability
of animals to rest on the plane fixed at two different an-
gles. Before treatment, there was a substantial and signifi-
cant difference between TG vehicle and WTgroups in this
test (Additional file 2B). After 9 weeks of treatment with
PXT3003, CMT1A rats showed significantly improvedperformance on the inclined plane that even reached the
level of performance of non-affected WT rats (Figure 4D).
CMT1A neuropathy is also characterised by sensory
impairment [43], which we measured in the CMT1A
rats using the hot plate [42]. We confirmed the reduced
heat sensitivity reported previously in this model [42].
The daily treatment with PXT3003 over 4 months re-
stored sensitivity of CMT1A rats almost to WT levels
(Figure 4E).
PXT3003 improves histological and electrophysiological
parameters in CMT1A rats
In order to confirm the clinical amelioration on the histo-
logical level, we examined sciatic nerve cross sections. In
untreated transgenic rats at the age of 5 months, we ob-
served a reduced number of myelinated fibres (Figure 5A),
evident both for small (diameter < 4 μm) and large (diam-
eter > 4 μm) axons (Figure 5B and D). Importantly, after
4 months of treatment with PXT3003, CMT1A TG rats
exhibited a significant 31% increase in the number of mye-
linated fibres per nerve cross section (Figure 5A). This oc-
curred mostly in small to middle-sized axons (Figure 5B
and D). However, similarly to the effect of onapristone
[13] in this model, PXT3003 failed to normalise another
myelination parameter: the distribution of g-ratio as a
function of axon diameter (Additional file 3A).
One consequence of dysmyelination in CMT1A disease
is an impairment of electrophysiological parameters such
as decrease of MNCV or of CMAP amplitude [43,44].
Figure 4 Daily oral treatment of CMT1A rats with PXT3003 down-regulates Pmp22 expression and reduces signs of motor and sensory
neuropathy. (A) A 9-week treatment with PXT3003 (BCL 30 μg/kg, NTX 3.5 μg/kg and SRB 1.05 mg/kg) decreased Pmp22 to Mpz mRNA ratio in the
sciatic nerve. n = 18, 20 and 18 animals for respectively WT vehicle, TG vehicle and TG PXT3003 groups. (B) Bar test. The latency to fall for transgenic rats
was significantly improved after 9 weeks of treatment with PXT3003. (C) Kaplan-Meier representation of the data set in (B) demonstrated a positive
effect of PXT3003. (D) After 9 weeks of treatment, the inclined plane score was significantly improved for transgenic rats. (B) to (D) n = 36, 38 and 36
animals for respectively WT vehicle, TG vehicle and TG PXT3003 groups. (E) A 4-month long PXT3003 treatment normalised the impaired thermal
sensitivity of transgenic rats in the hot plate test. n = 12, 10 and 7 animals respectively for WT, vehicle, TG vehicle and TG PXT3003 groups.
*P < 0.05; **P < 0.01; ***P < 0.001 vs TG vehicle; ANOVA with Dunnett’s test (except in (C), logrank). Data are shown as mean + SEM.
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MNCV was improved (Figure 5C). However, CMAP am-
plitudes had only a slight statistical trend for improvement
(Additional file 3B). All above treatment effects and dura-
tions in CMT1A rats are summarised in Additional file 4.
PXT3003 improves axonal myelination and regeneration
in a nerve crush model
To further assess the ability of PXT3003 to improve per-
ipheral nerve function, we used the in vivo sciatic nerve
crush model in mice. The nerve crush model is mostly
considered as a model of Wallerian degeneration but
demonstrates striking similarities to inherited demyelin-
ating neuropathies with common features of axonal de-
generation and dedifferentiation of Schwann cells [45].
In this model, nerve-crush damage results in temporalloss of function (lasting 30 days after nerve crush) ac-
companied by initial loss and gradual restoration of the
amplitude of CMAP (Additional file 5A) as well as by
the impairment of axonal morphological parameters (de-
crease of axonal calibre of the tibial nerve, impaired dis-
tribution of myelinated axons and of myelin g-ratio in
crushed nerves) in regenerating nerves (Additional file
5B to D). When mice were treated once a day with
PXT3003 starting 30 minutes after nerve crush, CMAP
amplitudes (Figure 6A) measured at 21 and 30 days were
largely normalised. At the end of a 42 day long drug
treatment, axonal morphology (Figure 6B), distribution
of myelinated fibres (Figure 6C), as well as the distribu-
tion g-ratio as an indicator of myelin thickness and/or of
the axonal diameter (Figure 6D) were also positively af-
fected in regenerating nerves.
Figure 5 Daily oral treatment of CMT1A rats with PXT3003 improves myelination and electrophysiology. A 4-month PXT3003 treatment
(BCL 30 μg/kg, NTX 3.5 μg/kg and SRB 1.05 mg/kg) of TG rats significantly increased the number of myelinated axons in sciatic nerve cross
sections (A) mostly in the small to medium sized axon class of myelinated axons (< 4 μm) (B). n = 12, 12 and 15 animals for respectively WT
vehicle, TG vehicle and TG PXT3003 groups. (C) 8-month PXT3003 treatment increased the motor nerve conduction velocity of TG rats in sciatic
nerve. n = 11, 9 and 7 animals for respectively WT vehicle, TG vehicle and TG PXT3003 groups. (D) Representative images of toluidine blue-stained
sciatic nerve cross sections for each group. Scale bar: 25 μm. *,+ P < 0.05; ** P < 0.01; ***P < 0.001 vs TG vehicle; ANOVA with Dunnett’s test
(except in (C), + t-test). Data are shown as mean + SEM.
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ation compared to single drugs in the functional behav-
ioural assay of paw surface bearing, where the surface
generated by paw pressure against the floor was mea-
sured [16]. In operated mice, unable to set down prop-
erly their affected paw to perform normal movements, a
substantial decrease in the surface bearing of the af-
fected hind paw was confirmed (Additional file 5E).
After treatment of mice with PXT3003, using doses used
in the experiments described above, no functional im-
provement was observed. However, when we increased
drug doses to a level that was still less than the range of
clinical use for their principal indications, i.e. 1/27 of the
approved dosage for BCL (80 mg/day), 1/147 of ap-
proved NTX (50 mg/day) and 1/147 of approved SRB
(15 g/day), PXT3003 was able to normalise completelythis functional defect (Figure 6E) in contrast to single
drugs that had no detectable effect (Figure 6F to H).
These results highlight a neuro-regenerative and pro-
myelinating potential of our drug combination.
We found no evidence of side-effects in any of the ani-
mal experiments described above (see Methods).
Discussion
It is striking that a small change in the copy number of
PMP22 (three compared to two) is responsible for axonal
loss in peripheral nerves, and consecutive muscle atrophy
and impaired sensitivity in affected individuals. Functional
integrity of myelin sheaths is highly sensitive to the stoi-
chiometry of its components, and any dysfunction in the
transcriptional network regulating expression of myelin
genes is potentially deleterious. Systems biology analysis of
Figure 6 Daily oral PXT3003 treatment of nerve-crushed mice restores nerve physiology, improves axonal and myelin integrity and
functional behaviour. (A) A 21 and 30 day-treatment with PXT3003 (BCL 60 μg/kg, NTX 7 μg/kg and SRB 2.1 mg/kg) increased the amplitude of
CMAP (measured in the gastrocnemius) of crushed nerves in male mice. n = 10 animals in each group. (B) to (D) A 42 day-treatment with
PXT3003 significantly improved axonal calibre size (B), normalised the distribution of the number of myelinated axons in terms of axonal
diameter (C) and improved the distribution of myelin g-ratio in tibial nerve cross sections (D). n = 6 for each group. (E) After 13 days of treatment,
PXT3003 (BCL 600 μg/kg, NTX 70 μg/kg and SRB 21 mg/kg) improved significantly the functional activity of crushed mice as assessed by the paw
surface pressure against the floor (paw surface bearing) of the affected paw normalised to the contralateral non-affected one. (F) to (H) In
contrast to PXT3003, single drugs had no effect on surface bearing ratio. n = 10 for each group. *P < 0.05, **P < 0.01, ***P < 0.001 vs Crush
Vehicle; t–test. Data are shown as mean ± SEM.
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tegral network of cellular signalling pathways implicated
in transcriptional regulation of the PMP22 gene. Theconverging point of this network is cAMP-dependent si-
lencer upstream of the PMP22 promoter. Three drugs:
baclofen, naltrexone and sorbitol, all binding to GPCR
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chosen among available authorised drugs with additional
criteria of safety and ability to affect other aspects of nerve
function. The underlying idea was that their combined ac-
tion will be more potent which could permit their use at
lower doses further minimising potential unwanted sec-
ondary effects. Other myelin genes can be potentially
down-regulated by these drugs, which necessitated an ex-
perimental verification of our underlying hypothesis.
We performed this primary analysis by testing the
three molecules in a disease-relevant ex vivo myelination
model derived from Pmp22 transgenic rats. While separ-
ately the three molecules were able to increase myelin-
ation, their common effect demonstrated a positive
synergistic interaction that provided a rationale for fur-
ther combination assays. In pilot experiments using cul-
tured Schwannoma cells, we were able to detect a
limited but significant down-regulation of Pmp22 gene
expression. The RT4-D6P2T Schwannoma cell line that
we used displayed features that resemble those of nor-
mal myelinating Schwann cells with the expression of
myelin genes at relatively high levels [46,47]. The extent
of the down-regulation observed was significantly higher
for the combination compared to the action of individ-
ual drugs. Expression of the major myelin gene Mpz was
not affected by these treatments, while Pmp22 gene ex-
pression (when normalised to that of Mpz) was de-
creased by the presence of PXT3003 but not by its
constitutive drugs. Interestingly, this specific effect on
Pmp22 but not on Mpz expression is similar to the effect
observed for the progesterone antagonist onapristone
[9]. We note that CMT1A is a gene dosage disease
where translation, processing and transport of PMP22
protein in Schwann cells is not yet fully elucidated and
only a small fraction of the protein is incorporated into
mature myelin [5]. Moreover, PMP22 protein and
mRNA expression in CMT1A patients is variable and no
correlation was found between PMP22 overexpression
and the Charcot-Marie-Tooth disease neuropathy score
(CMTNS) clinical score [42,48,49]. Future studies may
shed light on the effect of PXT3003 on the regulation of
PMP22 protein and other myelin proteins in peripheral
tissue of CMT1A patients.
Since PXT3003 proved efficacy over its single com-
pounds in the cellular models, we further tested the
combination drug in the transgenic rat model of
CMT1A. As patients included in clinical trials could
have manifested CMT1A for years before the beginning
of the trial, we used CMT1A adult rats for PXT3003
treatment. We also asked whether electrophysiological
amelioration could be expected after a long time of
treatment, i.e. 8 months, when the disease has reached
an advanced stage in the animal model. Here, we dem-
onstrated the beneficial effect of PXT3003 on theclinically relevant muscle motor performance and sen-
sory nerve function. Several biochemical, electrophysio-
logical and morphological characteristics such as the
ratio of Pmp22/Mpz gene expression in sciatic nerves,
small fibre myelination and MNCV were significantly
improved by PXT3003. Of note, the mild reduction in
Pmp22 expression after PXT3003 treatment (15%) is
reminiscent of the therapeutic effect of onapristone in
CMT1A rats [9]. We here argue that the reduction of
Pmp22 by PXT3003 improves peripheral nerve myelin-
ation and/or trophic support to axons leading to the in-
crease of the number of myelinated axons in the sciatic
nerve by 31%. At the same time, PXT3003 combination
had limited effect on CMAP and myelin g-ratio in this
CMT1A TG rat model in contrast to the acute in vivo
nerve crush model. Further work will be needed to see if
this increase in NCV without changes in myelin g-ratio
may be due to the changes in internodal lengths. We
note that the speed of nerve impulse propagation is also
determined by the internodal length, which could ex-
plain ameliorated NCV and unaltered CMAP. In
addition, we hypothesise that the absence of the effect
on CMAP at this moment may be due to the fact that
the treatment of TG rats had been started late, in early
adulthood when the disease was already at an advanced,
chronic stage. We note that in the progesterone antag-
onist therapy trial, a stronger therapeutic effect was ob-
served when treatment was initiated early postnatally
[9,13]. Also, early postnatal treatment of CMT1A rats
with soluble NRG corrected the dysmyelinating and ded-
ifferentiated Schwann cell phenotype [3]. Experiments
with an early onset treatment paradigm with PXT3003
in CMT1A rats are in progress and will also focus on its
effects on the differentiation state of Pmp22 transgenic
Schwann cells. Finally, we note that in the nerve crush
axonal regeneration model, PXT3003 administrated very
early, i.e. 30 minutes after nerve crush, accelerated the
process of axonal regeneration thus leading to the sig-
nificantly decreased proportion of small myelinated
axons and causing improvement in the amplitude of
CMAP. These observations might also raise the possibil-
ity that PXT3003 could modify directly axons activity
enabling their protection or regeneration, in agreement
with our initial hypothesis (Figure 1B).
The synergy observed in models permits the use of in-
dividual drugs at lower doses up to several hundred
times less than what is being used in their primary indi-
cations, diminishing potential undesirable secondary
effects.
Throughout this study, we focused on the validation of
the efficacy of PXT3003 in cellular and animal models
by assessing several CMT1A disease-relevant endpoints.
Our goal was more on the translational side to provide
the rationale for further testing in an affected human
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proof of principle for the repurposing of approved and
clinically safe drugs, using reproducible preclinical systems
with the main accent to genetic disease model. Many fea-
tures of CMT1A disease are far from being understood,
neither in rats nor in human patients. It is important to
keep in mind that, although for some endpoints the effect
in some models was significant but rather limited, it can
be considered as successful test of the hypothesis that ap-
proved drugs can be newly formulated to ameliorate a dis-
ease that they were not designed for.
Although designed from a series of mechanistic hy-
potheses, our preclinical data remains for the moment
mostly observational. More efforts must be performed
for a better understanding of exact mechanism of action
and the combinational synergy observed for PXT3003. It
will be particularly relevant to verify experimentally the
involvement of GABAB, opioid or muscarinic receptors
in the therapeutic effect reported here. Investigating the
mechanism of synergy could be even more challenging.
Launching these sophisticated and laborious mechanistic
experiments was out of scope of this study also because
of limited correlations generally observed for efficacy
when translating data in animal models to the human
clinical studies [50]. Finally, as the profile of PXT3003
seemed rather safe, taking into account the nature and
low doses of the 3 compounds, we decided to concen-
trate our efforts on its testing in an exploratory phase 2.
This has recently provided first indications of thera-
peutic activity in mild to moderately affected adult
CMT1A patients [51]. Altogether these data indicate
that PXT3003 deserves further clinical investigation as
well as experimental elucidation of its detailed mechan-
ism of action.Conclusions
In conclusion, the novel combination of three well-
known and approved drugs (baclofen, naltrexone and
sorbitol), identified by our Systems Biology approach, is
able to improve myelination in the ex vivo myelination
model of CMT1A, while single drugs displayed a lower
efficacy. The combination is also able to down-regulate
the expression of Pmp22 in cultured Schwannoma cells
more efficiently than single drugs. The tests performed
in vivo to assess the efficacy of the combination in the
nerve crush mouse model demonstrate the acute neuro-
regenerative and promyelinating potential of PXT3003
with the functional test demonstrating superiority of the
combined action. Moreover, PXT3003 combination im-
proves relevant parameters in the CMT1A rat model
(muscular performances, heat sensitivity, histology and
electrophysiology). No toxic effect of PXT3003 has been
detected in animal studies.Rational polytherapy based on a combinational reposi-
tioning of existing non-toxic drugs that act on pleiotropic
pathways, may represent an important novel approach for
rapid drug development in a variety of disorders. Future
work will show if a similar approach could be useful in the
treatment of other neglected orphan diseases where ther-
apies are urgently needed.Additional files
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